Synthetic DNA Nano Vaccines Enhance Killer T Cell Immunity
One of the advantages of synthetic DNA technologies over other methods is the versatility of the platforms
Researchers Designed DLnano Vaccines Displaying 60 Copies Of Protein Parts Derived From Melanoma-Specific Antigens Trp2 & Gp100 & Tested These In Mouse Models Of Melanoma.
Observing prolonged survival that depended on CD8 T cell activation both in therapeutic and prophylactic settings.
Said Ziyang Xu, Ph.D., A recent doctoral graduate working at Wistar and the first author of the study. “DLnano-vaccines may be designed for various cancer targets and our study shows this is a promising strategy for cancer immunotherapy that may warrant further testing.”
To elucidate the mechanism through which DL Nano Vaccines activate CD8 T cells, the team studied the effects of the DNA-launched version of a previously described HIV nanoparticle vaccine (eOD-GT8-60mer). They observed that DLnano-vaccines administered via electroporation resulted in transient muscle cell apoptosis that attracted macrophage infiltration at the injection site, which in turn was instrumental to activate CD8 T cells.
DLnano-vaccines were developed using synthetic DNA technology in collaboration with the lab of David B. Weiner, Ph.D., Wistar executive vice president, director of the Vaccine & Immunotherapy Center, and the W.W. Smith Charitable Trust Professor in Cancer Research and also a co-senior author on the study.
This news was originally published at sciencedaily.com